Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome. [Review] (Record no. 1409)

MARC details
000 -LEADER
fixed length control field 04127nam a22004817a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 130916s20122012 xxu||||| |||| 00| 0 eng dOvid Technologies
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1361-6137
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 22513976
245 ## - TITLE STATEMENT
Title Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome. [Review]
251 ## - Source
Source Cochrane Database of Systematic Reviews. 4:CD009807, 2012.
252 ## - Abbreviated Source
Abbreviated source Cochrane Database Syst Rev. 4:CD009807, 2012.
253 ## - Journal Name
Journal name The Cochrane database of systematic reviews
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2012
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2013
266 ## - Date added to catalog
Date added to catalog 2013-09-17
520 ## - SUMMARY, ETC.
Abstract AUTHORS' CONCLUSIONS: Data suggest that the effectiveness of MAOIs for the treatment of FM symptoms is limited. Although we observed a moderate effect size on pain and a small one on tender points, these results should be taken with caution as they are only based on two studies with a small number of patients and inconsistent risk of bias among them.
520 ## - SUMMARY, ETC.
Abstract BACKGROUND: Fibromyalgia (FM) syndrome is a chronic condition of unknown aetiology characterised by musculoskeletal pain that often co-exists with sleep disturbance, cognitive dysfunction and fatigue. Patients often report high disability levels and poor quality of life. Since there is no specific treatment that alters the pathogenesis of FM, drug therapy focuses on pain reduction and improvement of other bothersome symptoms.
520 ## - SUMMARY, ETC.
Abstract DATA COLLECTION AND ANALYSIS: Two authors assessed risk of bias and extracted data independently onto a specially designed pro forma and a third review author cross-checked them.
520 ## - SUMMARY, ETC.
Abstract MAIN RESULTS: We included two studies of inconsistent risk of bias with a total of 230 patients diagnosed with FM. We evaluated two MAOIs: pirlindole and moclobemide. Pirlindole showed statistically significant results compared with placebo for several outcomes (pain, tender points and overall assessment by the patient and the physician), whereas moclobemide did not show statistically significant differences between groups. Pooled results of the two studies displayed a modest effect size in pain (mean difference (MD) -1.45 (121 patients; 95% confidence interval (CI) -2.71 to -0.20; number needed to treat (NNT) 2 (95% CI 1 to 12); I(2) = 59%)), implying a minimal clinically important difference (MCID) and a small effect on tender points (standardised mean difference (SMD) -0.36 (121 patients; 95% CI -0.72 to -0.00; I(2) = 31%)). No effect was seen on global assessment by patient. Physical function and sleep disturbance were not measured. The most frequent adverse events were nausea and vomiting, with statistically significant differences between groups (risk ratio (RR) 7.82 (89 patients; 95% CI 1.02 to 59.97; NNT 7 (95% CI 4 to 33)).
520 ## - SUMMARY, ETC.
Abstract OBJECTIVES: The objective of this review was to assess the effectiveness and safety of monoamine oxidase inhibitors (MAOIs) in the treatment of FM syndrome.
520 ## - SUMMARY, ETC.
Abstract SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 10), MEDLINE (1966 to November 2010), EMBASE (1980 to November 2010) and the reference lists of reviewed articles.
520 ## - SUMMARY, ETC.
Abstract SELECTION CRITERIA: We selected all randomised, double-blind trials of MAOIs used for the treatment of FM pain in adult participants.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Carbazoles/tu [Therapeutic Use]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Fibromyalgia/dt [Drug Therapy]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Moclobemide/tu [Therapeutic Use]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Monoamine Oxidase Inhibitors/tu [Therapeutic Use]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adult
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Randomized Controlled Trials as Topic
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Syndrome
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Washington Hospital Center
656 ## - INDEX TERM--OCCUPATION
Department Medicine/Rheumatology
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
657 ## - INDEX TERM--FUNCTION
Medline publication type Meta-Analysis
657 ## - INDEX TERM--FUNCTION
Medline publication type Research Support, Non-U.S. Gov't
657 ## - INDEX TERM--FUNCTION
Medline publication type Review
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Walitt, Brian
790 ## - Authors
All authors Nishishinya MB, Tort S, Urrutia G, Walitt B
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="http://dx.doi.org/10.1002/14651858.CD009807">http://dx.doi.org/10.1002/14651858.CD009807</a>
Public note http://dx.doi.org/10.1002/14651858.CD009807
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 09/17/2013   22513976 22513976 09/17/2013 09/17/2013 Journal Article

Powered by Koha